Adherex Technologies, Inc.

Regulatory clearance granted for phase II trial of ADH-1 in Canada

Published in Lab Business Week, April 24th, 2005

Adherex Technologies, Inc., (ADH, AHX) announced that Health Canada has given regulatory clearance for the company's phase II Clinical Trial Application (CTA) for ADH-1, the company's lead anti-tumor biotechnology compound, also known as Exherin.

The phase II trial, which is expected to involve up to three cancer centers in Canada, will investigate repeated doses of ADH-1 in an every 3-week dosing schedule in patients whose tumors express the molecular target N-cadherin.

Specifically, the company will study eight different tumor types, including some more common ones such as breast and lung, as well as some rarer cancers such as adrenocortical and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2005-04-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry